Biomind Labs Inc. (BMNDF)
USD 0.7
(150.27%)
USD 0.7
(150.27%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 711.4 Thousand USD | 4053.55% |
| 2022 | -17.99 Thousand USD | 99.19% |
| 2021 | -2.22 Million USD | -2616.36% |
| 2020 | -82.03 Thousand USD | 75.47% |
| 2019 | -334.49 Thousand USD | 78.56% |
| 2018 | -1.56 Million USD | 66.34% |
| 2017 | -4.63 Million USD | -296.92% |
| 2016 | -1.16 Million USD | 46.18% |
| 2015 | -2.16 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 835.99 Thousand USD | 17.51% |
| 2024 Q2 | 994.44 Thousand USD | 18.95% |
| 2023 Q1 | -14.13 Thousand USD | 21.43% |
| 2023 Q3 | -129.01 Thousand USD | -111.72% |
| 2023 FY | 711.4 Thousand USD | 4053.55% |
| 2023 Q2 | -60.93 Thousand USD | -331.04% |
| 2023 Q4 | 711.4 Thousand USD | 651.41% |
| 2022 Q2 | -1 Million USD | 36.05% |
| 2022 FY | -17.99 Thousand USD | 99.19% |
| 2022 Q4 | -17.99 Thousand USD | 95.35% |
| 2022 Q1 | -1.56 Million USD | 29.56% |
| 2022 Q3 | -387.06 Thousand USD | 61.44% |
| 2021 Q2 | 47.26 Thousand USD | 1321.35% |
| 2021 FY | -2.22 Million USD | -2616.36% |
| 2021 Q1 | -3869.99 USD | 0.0% |
| 2021 Q4 | -2.22 Million USD | 27.41% |
| 2021 Q3 | -3.06 Million USD | -6594.85% |
| 2020 FY | -82.03 Thousand USD | 75.47% |
| 2019 FY | -334.49 Thousand USD | 78.56% |
| 2018 FY | -1.56 Million USD | 66.34% |
| 2017 FY | -4.63 Million USD | -296.92% |
| 2016 FY | -1.16 Million USD | 46.18% |
| 2015 FY | -2.16 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 54405.496% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 87.405% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 98.338% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 384.994% |
| Rebus Holdings, Inc. | 305 Thousand USD | -133.247% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 111.284% |
| Qrons Inc. | 351.42 Thousand USD | -102.432% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -14.306% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 98.362% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 3585.898% |
| Skye Bioscience, Inc. | -5.72 Million USD | 112.434% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 95.487% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 82.725% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -77.032% |
| SQZ Biotechnologies Company | -36.23 Million USD | 101.963% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 68.273% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 23.273% |
| Mesoblast Limited | 55.85 Million USD | 98.726% |
| Marizyme, Inc. | 18.56 Million USD | 96.169% |
| Genus plc | 190.6 Million USD | 99.627% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 68.182% |
| Pharming Group N.V. | 109.8 Million USD | 99.352% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 17.302% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 41.395% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -4.618% |
| ContraFect Corporation | -6.02 Million USD | 111.806% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -428.377% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 38.43% |
| IMV Inc. | 7.67 Million USD | 90.726% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 87.07% |
| MultiCell Technologies, Inc. | 90.04 USD | -789995.513% |
| ONE Bio Corp. | 9.04 Million USD | 92.131% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 196.924% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 94.505% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 47.996% |
| Q BioMed Inc. | 4.06 Million USD | 82.478% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 97.672% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 29.405% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 98.825% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 64.419% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 94.445% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -97.771% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -408.857% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -3480.822% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 67.693% |
| GB Sciences, Inc. | 1.74 Million USD | 59.286% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 487.078% |
| HST Global, Inc. | 96.79 Thousand USD | -634.973% |
| CSL Limited | 10.52 Billion USD | 99.993% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -244.977% |
| Halberd Corporation | 144.72 Thousand USD | -391.568% |
| Enzolytics Inc. | 981.65 Thousand USD | 27.53% |
| Agentix Corp. | 37.63 Thousand USD | -1790.468% |
| Resverlogix Corp. | 6.45 Million USD | 88.972% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 205.692% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.035% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 101.513% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 89.939% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 73.736% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 108.048% |
| AVAX Technologies, Inc. | -5.9 Million USD | 112.051% |
| Zenith Capital Corp. | 10.06 Thousand USD | -6968.78% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.067% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -254.934% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 70.185% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -332.44% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 3983.623% |
| Kadimastem Ltd | -253.1 Thousand USD | 381.073% |
| Helix BioMedix, Inc. | -2.57 Million USD | 127.681% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 96.491% |
| BioStem Technologies, Inc. | 4.47 Million USD | 84.092% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -253.485% |
| LadRx Corporation | -2.03 Million USD | 134.933% |
| Cell Source, Inc. | 9.23 Million USD | 92.294% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -12.002% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -12.002% |
| NovAccess Global Inc. | 2.17 Million USD | 67.344% |
| Affymax, Inc. | -5.59 Million USD | 112.71% |
| Itoco Inc. | 228.3 Thousand USD | -211.602% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -423.132% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 85.649% |
| Mobile Lads Corp. | 484.23 Thousand USD | -46.913% |
| CytoDyn Inc. | 20.26 Million USD | 96.489% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 110053.941% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 7775.614% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 90.768% |
| SYBLEU INC | 473.71 Thousand USD | -50.175% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 84.039% |
| International Stem Cell Corporation | 2.59 Million USD | 72.533% |
| Bioxytran, Inc. | 1.89 Million USD | 62.536% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1039.83% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 67.38% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 79.284% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 91.682% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 7.922% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 156.912% |
| Neutra Corp. | 52.18 Thousand USD | -1263.179% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 128.582% |
| PureTech Health plc | -167.19 Million USD | 100.425% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 390.477% |
| IXICO plc | -4.44 Million USD | 116.006% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 94.618% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 98.703% |
| CSL Limited | 10.52 Billion USD | 99.993% |
| Cellectis S.A. | -43.81 Million USD | 101.624% |